Mark Rothera - Sep 19, 2022 Form 4 Insider Report for Viracta Therapeutics, Inc. (VIRX)

Role: President and CEO, Director
Signature: /s/ Daniel Chevallard, as Attorney-in-Fact
Stock symbol: VIRX
Transactions as of: Sep 19, 2022
Transactions value $: $0
Form type: 4
Date filed: 9/19/2022, 07:04 PM
Next filing: Mar 17, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VIRX	Stock Option (Right to Buy)	Award	$0	+1.38M		$0.00	1.38M	Sep 19, 2022	Common Stock	1.38M	$5.21	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Twenty-five percent (25%) of the total shares subject to the Option will vest on the one (1)-year anniversary of the grant date and 1/48th of the total shares subject to the Option will vest each month thereafter on the same day of the month as the grant date (and if there is no corresponding day, the last day of the month), subject to the Reporting Person continuing to be a Service Provider in accordance with the Company's 2021 Inducement Equity Incentive Plan through each such date.

Content

Twenty-five percent (25%) of the total shares subject to the Option will vest on the one (1)-year anniversary of the grant date and 1/48th of the total shares subject to the Option will vest each month thereafter on the same day of the month as the grant date (and if there is no corresponding day, the last day of the month), subject to the Reporting Person continuing to be a Service Provider in accordance with the Company's 2021 Inducement Equity Incentive Plan through each such date.